Jean-Paul Salmon

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Marco Colleoni, Weixiu Luo, Per Karlsson et al. · The Lancet Oncology · 2017 · 120 citations

Breast Oncology, Medicine, Cancer Management +7

Delayed massive immune hemolysis mediated by minor ABO incompatibility after allogeneic peripheral blood progenitor cell transplantation

Jean-Paul Salmon, Simon P. Michaux, J.‐P. Hermanne et al. · Transfusion · 1999 · 59 citations · Full text

Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation

Frédéric Baron, André Gothot, Jean-Paul Salmon et al. · British Journal of Haematology · 2000 · 27 citations · Full text

Cell Therapy, Immunology, Pathology +20